Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05582161 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy Biomarkers of DAOIB for Dementia

StatusRecruiting
PhasePhase 2
Started2022-10-03
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 19, 2026 (before its estimated September 2026 completion). Its status may not reflect the trial's current state.

Amendment history

2026-03-18
Study Status v4
Primary completion date2025-09→2026-09
Completion date2025-09→2026-09
2024-02-06
Study Status v3
Re-verified, no change to tracked fields
2023-05-19
Study Status, Contacts/Locations v2
Study sitesdetails revised at 1 of 2 sites
2023-02-28
Study Status, Arms and Interventions, Contacts/Locations v1
Study sites1→2
Study arms0→1
2022-10-13
Original filing
This open-label clinical trial will enroll patients with aMCI or mild AD, and they will be treated with DAOIB for 24 weeks. We will assess the patients before entering the study, 8 weeks, 16 weeks, and end point (24 weeks) of the study, and measure blood NMDA and oxidative stress - related biomarkers every 8 weeks. We hypothesize that NMDA and oxidative stress - related biomarkers can predict the efficacy of DAOIB for patients with aMCI or mild AD.
Trial Details
NCT Number NCT05582161
Lead Sponsor Chang Gung Memorial Hospital
Conditions Dementia
Enrollment 123 participants
Start Date 2022-10-03
Primary Completion 2026-09 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-03-19